Long-term follow-up of therapeutic efficacy of everolimus-eluting bioresorbable vascular scaffold in comparison to everolimus-eluting stent in treatment of chronic total occlusion guided by intracoronary imaging

The Egyptian Heart Journal

Table 2 Clinical presentation on admission

Symptoms and signs		EES group	BVS group	Test	p value	Sig.
Symptoms and signs		No. = 40	No. = 20	Test	p value	Sig.
Chest pain	Negative	2 (5%)	0 (0%)	1.034	0.309	NS
Chest pain	Positive	38 (95%)	20 (100%)	1.034	0.309	NS
Dyspnea	Negative	29 (72.5%)	17 (85%)	1.165	0.281	NS
Dyspnea	Positive	11 (27.5%)	3 (15%)	1.165	0.281	NS
BP	Normal	40 (100%)	20 (100%)	–	–	–
SBP	Mean ± SD	112.98 ± 3.5	114.67 ± 3.22	1.809	0.076	NS
SBP	Range	100–120	100–120	1.809	0.076	NS
DBP	Mean ± SD	74.52 ± 1.7	74.80 ± 1.34	0.643	0.523	NS
DBP	Range	70–80	70–80	0.643	0.523	NS
Pulse	Mean ± SD	74.05 ± 5.81	72.45 ± 4.97	1.053^b	0.297	NS
Pulse	Range	60–86	65–76	1.053^b	0.297	NS
Murmur	No	29 (72.5%)	16 (80.0%)	0.400^a	0.527	NS
Murmur	MR	11 (27.5%)	4 (20.0%)	0.400^a	0.527	NS

BP blood pressure, SBP systolic blood pressure, DBP diastolic blood pressure, MR mitral regurgitation, NS non-significant, S significant
^aChi-square test
^bIndependent t test